Triphase-logo-Web.png
Triphase Accelerator Announces Positive Interim Results of Phase 1 Trial of TRPH-222 in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
07 déc. 2020 16h30 HE | Triphase Accelerator
TORONTO and SAN DIEGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MyoKardia, Inc. Buyout
05 oct. 2020 21h00 HE | Rigrodsky & Long, P.A.
WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating MyoKardia, Inc. (“MyoKardia”) (NASDAQ GS: MYOK) regarding possible breaches of...
BES_Mark.jpg
MYOKARDIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MYOK and Encourages Investors to Contact the Firm
05 oct. 2020 14h57 HE | Bragar Eagel & Squire
NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
logo-alt.png
Global Antidepressant Market: Increased Stress Levels over the Covid-19 Outbreak - PMI
30 juin 2020 10h40 HE | PMI
Covina, CA, June 30, 2020 (GLOBE NEWSWIRE) -- The global antidepressant market accounted for US$ 13.2 billion in 2019 and is estimated to be US$ 26.1 billion by 2029 and is anticipated to register a...
jounce.png
Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
04 juin 2020 08h00 HE | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Hausfeld logo
Celgene Rescinds Agreement to Compensate Cancer Patients Days Before Christmas
08 janv. 2020 13h36 HE | Hausfeld
WASHINGTON, Jan. 08, 2020 (GLOBE NEWSWIRE) -- On December 23, 2019, Celgene backed out of a settlement in which it had agreed to pay $55 million to end payors (consumers, insurers, union health and...
INVESTORS SAY EXECUTIVE PAY PACKAGES AT PHARMA MAY INCENTIVIZE DRUG PRICING RISKS
13 déc. 2017 13h13 HE | Azzad Funds
Falls Church, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SOURCE - AZZAD ASSET MANAGEMENT Investors today announced they have filed resolutions at five major pharmaceutical companies asking for information...
Rafarma Pharmaceuticals, Inc. logo
Rafarma Pharmaceuticals (RAFA) Commences Preparation of Audited Financials
12 mai 2014 09h15 HE | Rafarma Pharmaceuticals, Inc.
MOSCOW, May 12, 2014 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. (Pink Sheets:RAFA) has commenced a formal audit to provide additional transparency in its public filings with a forward view to...